Fig. 1.

The schedule of study. The intravenous infusions of HUC-MSCs at a dose of 10⁶ cells/kg or placebo were intravenously infused twice at day 1 and day 30. The quality of life, physical function, clinical laboratory parameters and inflammatory cytokines were assessed at baseline and follow-up visits. SAEs and AEs were collected within 6 months following the first treatment